In addition, the utility scores computed from the EQ-5D-5L instrument for Vietnamese patients receiving systemic treatment can be used in the health technology assessment of HER2-target drugs, especially in case of the heterogeneity in the utility scores of breast cancer patients among countries around the world. This evidence concerns the gene ERBB2 and breast carcinoma.